Table 1.
Baseline patients’ characteristics
| Crsrsctsristic | Sunitinib (N = 25) | |
|---|---|---|
| No. | % | |
| Age, years | ||
| Median | 65 | |
| Range | 33–82 | |
| Sex | ||
| Male | 20 | 80 |
| Female | 5 | 20 |
| ECOG performance status | ||
| 0 | 19 | 76 |
| 1 | 5 | 20 |
| 2 | 1 | 4 |
| Histology | ||
| Clear cell | 17 | 68 |
| Papillary | 4 | 16 |
| Undifferentiated | 1 | 4 |
| TF3 translocation | 2 | 8 |
| Mixed (clear cell and chromophobe) | 1 | 4 |
| Prior therapy | ||
| Target therapy | 4 | 16 |
| CT | 3 | 12 |
| IT | 3 | 12 |
| MSKCC risk factor | ||
| 0 (good) | 6 | 24 |
| 1–2 (intermediate) | 15 | 60 |
| 3 or plus (poor) | 4 | 16 |
| Heng risk factor | ||
| 0 (good) | 6 | 24 |
| 1–2 (intermediate) | 14 | 56 |
| 3 or plus (poor) | 5 | 20 |
| Line | ||
| First | 20 | 80 |
| Second | 3 | 12 |
| Third | 2 | 8 |
CT chemotherapy, ECOG Eastern Cooperative Oncology Group, IT immunotherapy with low doses of interleukin-2 and interferon-α, MSKCC Memorial Sloan Kettering Cancer Center